Incyte Genomics Inc (INCY) Price and Market Data

Incyte Genomics Inc focuses on the discovery and development of small-molecule medicines. Its flagship therapy, Jakafi, is used to treat two types of rare blood cancer as well as graft-versus-host disease and is partnered with Novartis. Other commercialized products include the rheumatoid arthritis treatment Olumiant, licensed to Lilly, and cancer therapies such as Iclusig for chronic myeloid leukemia, Pemazyre for cholangiocarcinoma, Tabrecta for lung cancer, and Monjuvi for diffuse large B-cell lymphoma. Incyte’s first dermatology product, Opzelura, received approval in 2021 for atopic dermatitis and in 2022 for vitiligo. The company’s pipeline features a broad portfolio of oncology and dermatology programs.